Vilde D. Haakensen

Oslo, Norway

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 46 publications

Prospective evaluation and clinical outcomes of adaptive radiotherapy for locally advanced non-small cell lung cancer (LA-NSCLC).

Prospective evaluation and clinical outcomes of adaptive radiotherapy for locally advanced non-small cell lung cancer (LA-NSCLC).

Journal: Acta oncologica (Stockholm, Sweden)

Published: March 25, 2026

Gut microbiota alterations in patients with non-small-cell lung cancer undergoing chemoradiotherapy.

Gut microbiota alterations in patients with non-small-cell lung cancer undergoing chemoradiotherapy.

Journal: Molecular oncology

Published: March 23, 2026

Mass spectrometry-based proteomics delivers in-depth proteome profiling of FFPE lung cancer biopsies from single glass slides.

Mass spectrometry-based proteomics delivers in-depth proteome profiling of FFPE lung cancer biopsies from single glass slides.

Journal: NPJ precision oncology

Published: January 20, 2026

ctDNA based MRD detection in stage III NSCLC treated with chemoradiotherapy and durvalumab.

ctDNA based MRD detection in stage III NSCLC treated with chemoradiotherapy and durvalumab.

Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

Published: January 03, 2026

Dual-time-point [18F]FDG-PET/CT as a prognostic biomarker in patients with pleural mesothelioma undergoing immunotherapy.

Dual-time-point [18F]FDG-PET/CT as a prognostic biomarker in patients with pleural mesothelioma undergoing immunotherapy.

Journal: EJNMMI research

Published: December 05, 2025

Quantitative [18F]PSMA-1007 PET in Treatment Response Monitoring of Brain Metastases from Non-small Cell Lung Cancer.

Quantitative [18F]PSMA-1007 PET in Treatment Response Monitoring of Brain Metastases from Non-small Cell Lung Cancer.

Journal: Molecular imaging and biology

Published: November 14, 2025

How does pulmonary function impact QoL in patients with locally advanced NSCLC treated with chemoradiotherapy and durvalumab?

How does pulmonary function impact QoL in patients with locally advanced NSCLC treated with chemoradiotherapy and durvalumab?

Journal: Acta oncologica (Stockholm, Sweden)

Published: November 12, 2025

Radiotherapy patterns and factors associated with pneumonitis in PACIFIC-R, a real-world study of patients with unresectable stage III non-small-cell lung cancer treated with durvalumab after chemoradiotherapy.

Radiotherapy patterns and factors associated with pneumonitis in PACIFIC-R, a real-world study of patients with unresectable stage III non-small-cell lung cancer treated with durvalumab after chemoradiotherapy.

Journal: Clinical and translational radiation oncology

Published: October 21, 2025

Real-world 5-year outcomes with durvalumab after chemoradiotherapy in unresectable stage III NSCLC.

Real-world 5-year outcomes with durvalumab after chemoradiotherapy in unresectable stage III NSCLC.

Journal: ESMO open

Published: September 11, 2025

Blood-based tumor mutational burden as a biomarker in unresectable non-small cell lung cancer treated with chemoradiotherapy and durvalumab.

Blood-based tumor mutational burden as a biomarker in unresectable non-small cell lung cancer treated with chemoradiotherapy and durvalumab.

Journal: Frontiers in oncology

Published: August 07, 2025

Toxicity Within 6 Months of Heterogeneous Fluorodeoxyglucose-Guided Radiotherapy Dose Escalation for Locally Advanced Non-Small Cell Lung Cancer in the Scandinavian Randomized Phase III NARLAL2 Trial.

Toxicity Within 6 Months of Heterogeneous Fluorodeoxyglucose-Guided Radiotherapy Dose Escalation for Locally Advanced Non-Small Cell Lung Cancer in the Scandinavian Randomized Phase III NARLAL2 Trial.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: April 18, 2025

Serum cytokines as a biomarker for immune checkpoint inhibitor toxicity in patients with pleural mesothelioma.

Serum cytokines as a biomarker for immune checkpoint inhibitor toxicity in patients with pleural mesothelioma.

Journal: Frontiers in immunology

Published: August 13, 2024

Showing 1-12 of 46

Last Updated: 09/26/2026